Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Dybdal, Kenneth Hargreaves, John Madigan, D. Gribble, P. Kennedy, G. Stabenfeldt (1994)
Diagnostic testing for pituitary pars intermedia dysfunction in horses.Journal of the American Veterinary Medical Association, 204 4
D. Orth, W. Nicholson (1982)
Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease.Endocrinology, 111 2
D. Peters, J. Erfle, G. Slobojan (1995)
Low-dose pergolide mesylate treatment for equine hypophyseal adenomas (Cushing's syndrome), 41
C. Semple, G. Beastall, C. Gray, J. Thomson (1983)
Trilostane in the management of Cushing's syndrome.Acta endocrinologica, 102 1
C. Irvine, S. Alexander (1994)
Factors affecting the circadian rhythm in plasma cortisol concentrations in the horse.Domestic animal endocrinology, 11 2
Andrews (1997)
Diagnosis of pituitary adenoma by using a combined dexamethasone suppression, and TRH stimulation testProc. Am. Ass. equine Practnrs., 43
J. Beech, M. Garcia (1985)
Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma.American journal of veterinary research, 46 9
Reto Neiger, I. Ramsey, J. O'Connor, Karyl Hurley, Carmel Mooney (2002)
Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticismVeterinary Record, 150
R. Douglas (1999)
Circadian cortisol rhythmicity and Equine Cushing's-like diseaseJournal of Equine Veterinary Science, 19
G. Perkins, S. Lamb, H. Erb, B. Schanbacher, D. Nydam, T. Divers (2010)
Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.Equine veterinary journal, 34 7
Witt Witt, Neiger Neiger (2003)
Endogenous plasma adrenocorticotrophic hormone before and after therapy with trilostane for pituitary dependent hyperadrenocortiscismVet. Rec.
H. Schott, Cynthia Coursen, S. Eberhart, Raymond Nachreiner, K. Refsal, S. Ewart, J. Marteniuk (2001)
The Michigan Cushing's Project
H. Eiler, J. Oliver, F. Andrews, K. Fecteau, E. Green, M. Mccracken (1997)
Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma.Journal of the American Veterinary Medical Association, 211 1
Perkins Perkins, Lamb Lamb, Erb Erb, Schanabacher Schanabacher, Nydam Nydam, Divers Divers (2001)
Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptidine or pergolideJ. vet. intern. Med., 15
M. Wilson, W. Nicholson, M. Holscher, B. Sherrell, C. Mount, D. Orth (1982)
Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.Endocrinology, 110 3
Sandy Love (1993)
Equine Cushing's disease.The British veterinary journal, 149 2
W. Millington, N. Dybdal, R. Dawson, C. Manzini, G. Mueller (1988)
Equine Cushing's disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary.Endocrinology, 123 3
Summary Reasons for performing study: Trilostane, a competitive 3‐beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism Objectives: Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety. Methods: Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4–1 mg/kg (mean 0.5 mg/kg) trilostane once daily. Results: Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 ± 53.0 nmol/l) and after (130 ± 46.1 nmol/l) trilostane. Conclusions: Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration. Potential relevance: Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.
Equine Veterinary Journal – Wiley
Published: Jun 1, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.